Edition:
India

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

5.07USD
2:29am IST
Change (% chg)

$-0.22 (-4.16%)
Prev Close
$5.29
Open
$5.28
Day's High
$5.28
Day's Low
$5.06
Volume
15,718
Avg. Vol
15,759
52-wk High
$9.76
52-wk Low
$3.60

Latest Key Developments (Source: Significant Developments)

Catabasis Pharmaceuticals Inc Quarterly Loss Per Share $0.62
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.62.CATABASIS PHARMACEUTICALS INC SAYS AS OF JUNE 30, 2019, THE COMPANY HAD AVAILABLE CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $46.1 MILLION.  Full Article

Catabasis Pharmaceuticals Reports Q2 Loss Per Share $0.62
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q2 LOSS PER SHARE $0.62.Q2 EARNINGS PER SHARE ESTIMATE $-0.61 -- REFINITIV IBES DATA.CATABASIS PHARMACEUTICALS - AS OF JUNE 30, CO HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $46.1 MILLION, VERSUS $51.7 MILLION AS OF MARCH 31, 2019.EXPECTS THAT IT HAS SUFFICIENT CASH TO FUND OPERATIONS BEYOND TOP-LINE PHASE 3 RESULTS AND THROUGH 2020.  Full Article

Catabasis Pharmaceuticals Reports Q4 Loss Per Share Of $0.85
Thursday, 14 Mar 2019 

March 14 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q4 LOSS PER SHARE $0.85.Q4 EARNINGS PER SHARE ESTIMATE $-0.90 -- REFINITIV IBES DATA.AS OF DECEMBER 31, 2018, CATABASIS HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $37.6 MILLION.  Full Article